Understanding immune responses to monkeypox vaccination in high-risk individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the immune responses, both humoral and cellular, following vaccination against monkeypox in individuals at high risk, including those living with HIV. It focuses on the effectiveness of the MVA-BN vaccine, which has been recently approved for intradermal administration during the current monkeypox outbreak. The study will monitor participants' immune responses to better understand the vaccine's performance in a population significantly affected by monkeypox. The findings could provide valuable insights into vaccination strategies for high-risk groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult individuals of ≥18 years old.
2. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the trial.
3. Has understood the information provided and capable of giving informed consent.

Exclusion Criteria:

1\. Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.

Where it's running

• Germans Trias i Pujol Hospital
  Badalona, Barcelona, Spain Recruiting
• BCN Checkpoint
  Barcelona, Barcelona, Spain Recruiting
• VALLE HEBRÓN HOSPITAL/Centro Salud Internacional y Enfermedades Transmisibles Drassanes
  Barcelona, Barcelona, Spain Not yet recruiting

Study contacts

• Study coordinator: Beatriz Mothe, PhD, MD
• Email: bmothe@irsicaixa.es
• Phone: 676142408

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety, tolerability, and how the body processes BSY001 after single and multiple doses

  This trial will test whether BSY001 is safe, well tolerated, and how it is absorbed and cleared when given once or multiple times to healthy adults aged 18–50.

  Recruiting Phase 1 China National Biotec Group Company Limited · Hangzhou · NCT07377175

• Evaluating the long-term effects of a booster dose of MVA-BN vaccine for monkeypox

  This study is testing how well a booster dose of the MVA-BN vaccine works over time in men over 18 who have already had two doses to help protect against monkeypox.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, Paris · NCT06885853

• Two-dose MVA monkeypox live vaccine in adults

  This trial will test whether two doses of an MVA-strain monkeypox live vaccine are safe and produce an immune response in adults, including healthy people, men who have sex with men, and people living with HIV.

  Recruiting Phase 1 Shanghai Institute Of Biological Products · Zhengzhou, Henan · NCT06771479

• Follow-up of monkeypox cases and smallpox vaccine recipients

  This project will follow adults who had monkeypox and people who received smallpox vaccine doses to see if immune responses remain strong over time and if any lasting physical or psychological effects develop.

  Recruiting Institute of Tropical Medicine, Belgium · Antwerp · NCT05879965

• Observational study of monkeypox infection in Brazil

  This study is trying to see how different health factors affect the risk and severity of monkeypox in people in Brazil.

  Recruiting at 3 sites Hospital Israelita Albert Einstein · Belém, Pará and 2 other locations · NCT05784038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.